Cromos Pharma, where the patients are

Drug Sponsors

Johnson & Johnson, Janssen Pharmaceuticals, Scios finalize Risperdal settlements, will pay $2 billion

Monday, November 4, 2013 02:18 PM

Johnson & Johnson and its subsidiaries, Janssen Pharmaceuticals and Scios have finalized previously disclosed settlement agreements with the U.S. Department of Justice (DOJ) and 45 states resolving federal investigations and state Medicaid claims related to past promotional practices of Risperdal (risperidone) from 1999 through 2005, and other matters. The resolution includes total settlement amounts of approximately $2 billion to the federal government and state Medicaid programs, an amount previously accrued, and no additional charge to the company’s earnings will be recorded in connection with this settlement.

More... »

CRF Health eCOA webinar series

Teva announces departure of president and CEO Jeremy Levin

Monday, November 4, 2013 01:38 PM

Teva Pharmaceutical Industries said its board of directors has agreed with Dr. Jeremy Levin’s decision to step down as president and chief executive officer. The board has named Eyal Desheh, Teva's executive vice president and chief financial officer, to fill the role of president and chief executive officer on an interim basis, effective immediately, and it has formed a committee to search for a permanent successor.

More... »

Fidelity Biosciences, Regenx Biosciences launch Dimension Therapeutics

Friday, November 1, 2013 11:10 AM

Fidelity Biosciences and Regenx Biosciences have formed Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension will focus on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia and building out a product engine for AAV therapeutics.

More... »

ThermoGenesis reorganizes, eliminates 11 positions

Friday, November 1, 2013 11:09 AM

ThermoGenesis, a developer and manufacturer of automated blood and bone marrow processing systems, has announced a reorganization initiative designed to better align resources with its expected cord blood revenue streams, increase its internal clinical resource capabilities and provide greater focus on new application development to improve the company's market competitiveness and to speed AXP AutoXpress Platform (AXP) adoption in developed and emerging markets.

More... »

Gilead Alberta expands research and manufacturing facility in Canada

Wednesday, October 30, 2013 03:52 PM

Gilead Alberta, a fully integrated research and manufacturing facility of Gilead Sciences Canada, has announced a $47 million expansion of its research and manufacturing facility in Edmonton, Alberta. The expansion will create more than 80 full-time positions at Gilead Alberta and increase the size of the facility by 45,000 square feet to create new laboratory and research space. 

More... »

Vertex cuts workforce 15%

Wednesday, October 30, 2013 11:12 AM

Global biotech Vertex Pharmaceuticals will focus its investment on future opportunities in cystic fibrosis and other high-potential R&D programs and is reducing its workforce related to the support of INCIVEK, because of the continued and rapid decline in the number of people being treated with INCIVEK as other new medicines for hepatitis C near approval.

More... »

Regeneron, BioMed Realty break ground on New York R&D facility

Monday, October 28, 2013 02:36 PM

Regeneron Pharmaceuticals and BioMed Realty Trust have broken ground on a new 300,000-square-foot build-to-suit research facility for Regeneron at BioMed Realty's The Landmark at Eastview campus in Westchester County, New York.

More... »

McKesson to acquire Celesio for $8.3 billion

Monday, October 28, 2013 02:34 PM

McKesson, a North American healthcare services and information technology company, has signed an agreement to acquire a majority stake in Celesio, an international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, for $32 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio. The offer price represents a 39% premium over the three-month volume weighted average price prior to the market speculation that began Oct. 8. The total transaction, including the assumption of Celesio’s outstanding debt, is valued at approximately $8.3 billion.

More... »

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Monday, October 28, 2013 02:22 PM

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

More... »

Illumina to acquire NextBio

Monday, October 28, 2013 02:20 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function based in San Diego, will acquire Santa Clara-based NextBio, a provider of clinical and genomic informatics.

More... »

CenterWatch Data Library



Browse by:


April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs